Persistently Elevated Levels of von Willebrand Factor Antigen in HIV Infection

Summary

Levels of circulating von Willebrand factor (vWf) antigen are thought to reflect endothelial involvement in various disorders. In the present study we found markedly elevated plasma levels of vWf in HIV-infected patients demonstrated on both cross-sectional and longitudinal testing. Notably, we found that a persistent rise in vWf antigen was associated with progression of HIV-related disease. This elevation of vWf antigen represented functionally normal vWf as evaluated by plasma FVIII, ristocetin cofactor assay and vWf multimer analyses. While HIV-infected patients showed enhanced platelet activation, platelets did not contribute substantially to the increased vWf levels. The high vWf levels were significantly correlated with high viral load, and during HAART, the pronounced decline in HIV RNA levels was accompanied by a corresponding decrease in vWf. The persistent elevation of functionally normal vWf during HIV infection, most probably reflecting a persistent endothelial cell activation, may have an important role in the pathogenesis of HIV infection.

Keywords

von Willebrand factor - HIV infection - endothelial cells - platelets - highly active antiretroviral therapy

• References

• 1 Macay CR, Imhof BA. Cell adhesion in the immune system. Immunol Today 1993; 14: 99-102.
• 2 Zietz C, Hotz B, Stürzl M, Rauch E, Penning R, Löhrs U. Aortic endothelium in HIV-1 infection. Am J Pathol 1996; 149: 1887-98.
• 3 Hofman FM, Wright AD, Dohadwala MM, Wong-Staal F, Walker SM. Exogenous tat protein activates human endothelial cells. Blood 1993; 82: 2774-80.
• 4 Constans J, Seeigneur M, Blann AD, Renard M, Resplandy F, Amiral J, Guerin V, Boisseau MR, Conri C. Effect of the antioxidants selenium and β-carotene on HIV-related endothelium dysfunction. Thromb Haemost 1998; 80: 1015-7.
• 5 Schved J-F, Gris J-C, Arnaud A, Martinez P, Sanches N, Wautier J-L, Sarlat C. Von Willebrand factor antigen, tissue-type plasminogen activator antigen, and risk of death in human immunodeficiency virus-1 related clinical disease: independent prognostic relevance of tissue-type plasminogen activator. J Lab Clin Med 1992; 120: 411-9.
• 6 Seigneur M, Constans J, Blann A, Renard M, Pellegrin JL, Amiral J, Baisseau M, Conri C. Soluble adhesion molecules and endothelial cell damage in HIV infected patients. Thromb Haemost 1997; 77: 646-9.
• 7 Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 06: 217-46.
• 8 Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders?. Cardiovasc Res 1997; 34: 255-65.
• 9 Rubin DB, Wiener-Kronish JP, Murray JF, Green DR, Turner J, Lace JM, Montgomery AB, Marks JD, Matthay MA. Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. J Clin Invest 1990; 86: 474-80.
• 10 Mannucci PM. Von Willebrand factor – a marker of endothelial damage?. Arterioscler Thromb Vasc Biol 1998; 18: 1359-62.
• 11 Holme PA, Müller F, Solum NO, Brosstad F, Frøland SS, Aukrust P. Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB J 1998; 12: 79-90.
• 12 Centers for disease control and prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1993; 41: 1-19.
• 13 Solum NO, Olsen TM, Gogstad GO, Hagen I, Brosstad F. Demonstration of a new glycoprotein 1b-related component in platelet extracts prepared in the presence of leupeptin. Biochem Biophys Acta 1983; 729: 53-61.
• 14 Aukrust P, Liabakk N-B, Müller F, Lien E, Espevik T, Frøland SS. Serum levels of tumor necrosis factor (TNF)α and soluble TNF receptors in human immunodeficiency virus type 1 infection – correlations to clinical, immunologic, and virologic parameters. J Infect Dis 1994; 169: 420-4.
• 15 Brosstad F, Kjønniksen I, Rønning B, Stormorken H. Visualization of von Willebrand factor multimers by enzyme-conjugated secondary antibodies. Thromb Haemost 1986; 55: 276-8.
• 16 Boda Z, Solum NO, Sztaricskai F, Rak K. Study of platelet agglutination induced by antibiotics of the vancomycin group: ristocetin, ristomycin, actinoidin and vancomycin. Thromb Haemost 1979; 42: 1464-80.
• 17 Mannucci PM. Platelet von Willebrand factor in inherited and acquired bleeding disorders. Proc Natl Acad Sci USA 1995; 92: 2428-34.
• 18 McCaroll DR, Waters DC, Steidlet KR, Clift R, McDonald TP. Canine platelet von Willebrand factor quantification and multimeric analysis. Exp Hematol 1998; 16: 929-37.
• 19 Gulick RM. HIV treatment strategies. JAMA 1998; 279: 957-9.
• 20 Périard D, Telenti A, Sudre P, Cheseaux J-J, Halfon P, Reymond MJ, Marcovina SM, Glauser MP, Nicod P, Darioli R, Mooser V. Swiss HIV Cohort Study. Atherogenic dyslipidemia in HIV infected individuals treated with protease inhibitors. Circulation 1999; 100: 700-5.
• 21 Zidovetzki R, Wang J-L, Chen P, Jeyaseelan R, Hofman F. Human immunodeficiency virus tat protein induces interleukin 6 mRNA expression in human brain endothelial cells via protein C- and cAMP-dependent protein kinase pathway. AIDS Res Human Retroviruses 1998; 14: 825-33.
• 22 Flore O, Rafii S, Ely S, O’Leary JJ, Hyjek EM, Cesarman E. Transformation of primary human endothelial cells by Kaposi’s sarcoma associated herpesvirus. Nature 1998; 394: 588-92.
• 23 Saukkkonen JJ, Furfaro S, Mahoney KM, Strieter RM, Burdick M, Wright EA, Kornfeld H, Berman JS. In vitro transendothelial migration of blood T lymphocytes from HIV-infected individuals. AIDS 1997; 11: 1595-601.
• 24 Bragardo M, Buonfiglio D, Feito MJ, Bonissoni S, Redoglia V, Rojo JM, Ballester P, Garbarino G, Malavasi F, Dianzani U. Modulation of lymphocyte interaction with endothelium homing by HIV-1 gp 120. J Immunol 1997; 159: 1619-27.